Be the first to know

Never miss an update from AMAG Pharmaceuticals. Did you know that during reporting season, the announcements from NASDAQ:AMAG often move the market?

AMAG Pharmaceuticals (NASDAQ:AMAG) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow AMAG

AMAG Pharmaceuticals (AMAG)

US NASDAQ:AMAG (322.2M)

9.50
+0.09 (0.90%)
4:30pm Friday Feb 21 EST
LOADING
Loading price chart..

Summary

Current Price: $9.50
52w High/Low: $6.81 - 15.99
Market Cap: 322.2M
Price/Earnings: -1.13
Dividend Yield: -
Volume/Average: 544K - 889K
AMAG Pharmaceuticals (NASDAQ:AMAG) Company Logo
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia... More
AMAG Pharmaceuticals (NASDAQ:AMAG) Company Logo

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Annual Reports

AMAG Pharmaceuticals (AMAG) 10-K Annual Report Mar 1st 2019
2019
(164kb)
AMAG Pharmaceuticals (AMAG) 10-K Annual Report Mar 1st 2018
2018
(144kb)
AMAG Pharmaceuticals (AMAG) 10-K Annual Report Feb 21st 2017
2017
(1.4mb)
AMAG Pharmaceuticals (AMAG) 10-K Annual Report Feb 24th 2016
2016
(1.7mb)

Dividend History

No dividends found.

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Implied Growth
36.0%
 
99.2%
 
 
Industry Avg
AMAG

UNATTRACTIVE: AMAG Pharmaceuticals exhibits an implied growth ratio which exceeds the industry average for pharmaceuticals: major stocks listed on the NASDAQ. AMAG calculation: 10% - (-$8.47 / $9.50) = 99.2% more
Price / Book
5.3
 
0.7
 
 
Industry Avg
AMAG

ATTRACTIVE: AMAG Pharmaceuticals exhibits a price/book ratio which is less than the industry average for pharmaceuticals: major stocks listed on the NASDAQ. more
Price / Sales
9.8
 
1.0
 
 
Industry Avg
AMAG

ATTRACTIVE: AMAG Pharmaceuticals exhibits a price/sales ratio which is less than the industry average for pharmaceuticals: major stocks listed on the NASDAQ. more

Company News

AMAG Pharmaceuticals' Q3 Results Overshadowed by Ominous FDA Panel Recommendation
November 1st, 2019 - Motley Fool

The drugmaker's Q3 results didn't matter very much in light of the prospect that it might have to yank Makena from the market.

Q3 2019 Earnings Call Transcript
November 1st, 2019

Q3 2019 Earnings Call Transcript

Why AMAG Pharmaceuticals Is Tanking Today
October 30th, 2019 - Motley Fool

Shares tumble after an FDA advisory committee recommends pulling one of the company's key drugs from the market. Here are the must-know details.

Why AMAG Pharmaceuticals Stock Jumped Today
August 12th, 2019 - Motley Fool

It continues to enjoy a strong rebound after a sell-off last week that investors seem to think was overdone.

What's Behind AMAG Pharmaceuticals' Horrible Q2 Results
August 7th, 2019 - Motley Fool

The drugmaker exited a key market, causing its top and bottom lines to tank in the second quarter.

Q2 2019 Earnings Call Transcript
August 7th, 2019

Q2 2019 Earnings Call Transcript

Why Palatin Technologies Stock Dropped as Much as 21.5% Today
June 25th, 2019 - Motley Fool

A high-profile analyst questioned the company's recent FDA approval.

3 Drug Stocks That Could Win From Key FDA Approvals in June
June 4th, 2019 - Motley Fool

Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.